This is a working overview of actin-binding fragment, written for readers who want more than a one-paragraph summary but less than a textbook.
This page was last updated on 2025-08-21 and is reviewed periodically as new material appears.
Thymosin beta-4 is a naturally occurring protein of 43 amino acids found in most mammalian cells, where it binds actin monomers and influences filament dynamics. It was first isolated from thymus tissue in the early 1980s, and its actin-binding activity was later mapped to a short region near the N-terminus. The synthetic fragment sold as TB-500 was designed to reproduce that region rather than the full protein. Whether a short fragment reproduces the behavior of the intact molecule remains an open question, since the parent protein carries additional structural elements outside the binding region.
Published research on the intact protein is substantial, covering actin regulation, cell migration, and wound models. Research using the heptapeptide fragment specifically is far smaller, and much of the circulating material originates in supplier documentation rather than peer-reviewed reports. Where fragment studies do exist, they often employ different sequences, chain lengths, or terminal modifications, which complicates direct comparison across papers. Readers encountering claims about TB-500 should therefore separate evidence about thymosin beta-4 from evidence about the fragment itself.
Sports authorities classify the peptide as a prohibited substance, and it appears on the World Anti-Doping Agency list under peptide hormones, growth factors, and related substances. Racing jurisdictions for horses and dogs have issued separate restrictions, and several national bodies treat it as a controlled or prescription-only item. As a research chemical it is sold without a therapeutic indication, and labels usually state that the product is not for human or veterinary use. Regulatory treatment therefore varies by country.
Detection in biological matrices generally relies on liquid chromatography coupled with tandem mass spectrometry, because the peptide lacks a convenient ultraviolet chromophore beyond the amide backbone. Immunoassays have been described, but antibodies raised against the fragment can cross-react with the full-length protein or with unrelated peptides, so findings usually require confirmation by a second technique. Sample preparation typically involves protein precipitation followed by solid-phase extraction. Reported detection windows depend on dose, route, matrix, and instrument sensitivity.
| Property | Value | Notes |
|---|---|---|
| Reported sequence | Ac-LKKTETQ | Described in most listings as the actin-binding region of thymosin beta-4 |
| Reported molecular weight | Approximately 889 Da | Value shifts with the stated sequence; compare against the certificate of analysis |
| Parent protein length | 43 amino acids | Thymosin beta-4; the fragment covers only a small part of it |
| Common synonyms | TB4 fragment; thymosin beta-4 fragment | Trade-style names rather than formal nomenclature |
| Formal monographs | Not established | Labeling conventions differ by supplier and region |
Thymosin beta-4 contains 43 amino acids and has a reported molecular mass near 4963 Da. The short fragment most often associated with the TB-500 label, an acetylated chain beginning LKKTETQ, has a reported mass near 889 Da, so the two are easily separated in analytical work. Mass spectrometry and amino acid analysis can confirm which material is present in a given sample. Statements treating TB-500 and thymosin beta-4 as interchangeable are therefore imprecise, even though the two appear together in much of the same literature.
Interest in the compound comes largely from studies of the parent protein, which participates in actin sequestration, cell migration and tissue repair processes. Whether a short fragment reproduces those activities is a separate question that remains open in the published record. Many summaries describe mechanisms by analogy to thymosin beta-4 rather than from direct measurements on the fragment. Claims about activity should be treated as provisional unless a cited study specifies the exact peptide, its purity and the assay used.
TB-500 is a laboratory label applied to a short synthetic peptide that is widely described as a fragment of thymosin beta-4, an actin-binding protein present in most mammalian cells. Suppliers and review articles usually present TB-500 as the N-terminal region of that protein, but the exact sequence attached to the name is not consistent across sources. Some product descriptions list a seven-residue chain; others use the label loosely for the parent protein itself. Because of that variation, any technical discussion of TB-500 needs to state which sequence is meant.
Biological interest in this peptide centers on its relationship to actin dynamics. Thymosin beta-4 binds monomeric actin through an LKKTET motif, and a short sequence carrying that motif can compete with other actin-binding proteins in cell-free preparations. Investigators propose that such competition shifts the balance between filament assembly and disassembly, which in turn affects how readily a cell extends protrusions and migrates. Most of the supporting observations come from cultured cells and purified protein systems rather than from intact organisms.
Animal work has examined the peptide in models of cardiac injury, skin wounding, and corneal repair, with reported outcomes covering cell migration, inflammatory cell influx, and tissue remodeling. Several of those experiments used the full-length protein or longer fragments instead of the seven-residue sequence, which makes direct comparison between reports difficult. Results are generally described as tissue-dependent, and effect sizes vary considerably across laboratories. Independent replication is uneven, so the overall picture is incomplete rather than settled.
Proposed activity centers on actin sequestration and on the movement of cells during repair processes. In cell culture and animal models, the fragment has been associated with migration, tube formation, and tissue remodeling. These observations are frequently described as preliminary, because most published work uses rodent or in vitro systems rather than controlled human trials. Whether the short fragment reproduces the effects of the full protein remains an open question, and the relationship between dose, route, and measured outcome is not well characterized.
The compound circulates in the literature as a research reagent rather than an approved therapeutic. Regulatory agencies in several countries have not authorized it for medical use, and sporting bodies list related thymosin beta-4 peptides among prohibited substances. Suppliers typically market it with a purity figure and a certificate of analysis, while peer-reviewed clinical reports remain sparse. Discussions therefore often separate laboratory findings from anecdotal reports, and reviewers tend to note the small size and methodological limits of the available studies.
TB-500 refers to a synthetic peptide fragment derived from the actin-binding region of thymosin beta-4, a protein present in most mammalian cells. The full protein contains forty-three amino acids, while the commonly sold fragment is a much shorter acetylated sequence, often cited as LKKTETQ. The fragment retains part of the actin-binding motif but lacks the remainder of the parent protein. Material sold under this name is usually lyophilized powder intended for laboratory research, and it is not a finished pharmaceutical product.
Lyophilized TB-500 is hygroscopic and should be kept dry before use. The usual storage recommendation for the solid is -20 °C, protected from light and moisture. Once dissolved, the peptide is less stable, and repeated freeze-thaw cycles can promote aggregation or degradation. Laboratories often divide a reconstituted solution into single-use aliquots and store them at -80 °C. Exact stability limits depend on buffer, pH, and concentration, so published data do not define a single universal condition.
Identity and purity are checked with chromatographic and mass spectrometric methods. Reverse-phase high-performance liquid chromatography separates the peptide from related impurities, while mass spectrometry confirms the expected molecular mass. A certificate of analysis may report a purity percentage, but the laboratory should still verify the material independently. Common quality concerns include truncated sequences, deamidation, oxidation, and residual solvents from synthesis. Because TB-500 is short, some impurities can differ from the target by only a few mass units.
Reconstitution practices affect downstream measurements. The dry powder is typically dissolved in sterile water or a suitable aqueous buffer, then mixed gently rather than vortexed at high speed. Visible particles or cloudiness suggest incomplete dissolution or contamination and should be investigated. For long-term storage, aliquots should be labeled with concentration, solvent, and date. Open questions include how different buffers alter peptide conformation and whether specific container materials adsorb the peptide. Those variables can change apparent concentration in assays even when the chemical identity is correct.
== Ion exchange resins == Ion exchange resins are the physical medium that facilitates ion exchange reactions. The resin is composed of cross-linked organic polymers, typically polystyrene matrix and functional groups where the ion exchange process takes place.
=== Termination === The phosphorylation of PAR1's cytoplasmic tail and subsequent binding to arrestin uncouples the protein from G protein signaling. These phosphorylated PAR1s are transported back into the cell via endosomes where they are sent to Golgi bodies. The cleaved PAR1s are then sorted and transported to lysosomes where they are degraded. This internalization and degradation process is necessary for the termination of receptor signaling.
The sixth row of the table likewise starts with two s-block elements: caesium and barium. After this, the first f-block elements (coloured green below) begin to appear, starting with lanthanum. These are sometimes termed inner transition elements. As there are now not only 4f but also 5d and 6s subshells at similar energies, competition occurs once again with many irregular configurations; this resulted in some dispute about where exactly the f-block is supposed to begin, but most who study the matter agree that it starts at lanthanum in accordance with the Aufbau principle. Even though lanthanum does not itself fill the 4f subshell as a single atom, because of repulsion between electrons, its 4f orbitals are low enough in energy to participate in chemistry. At ytterbium, the seven 4f orbitals are completely filled with fourteen electrons; thereafter, a series of ten transition elements (lutetium through mercury) follows, and finally six main-group elements (thallium through radon) complete the period. From lutetium onwards the 4f orbitals are in the core, and from thallium onwards so are the 5d orbitals. The seventh row is analogous to the sixth row: 7s fills (francium and radium), then 5f (actinium to nobelium), then 6d (lawrencium to copernicium), and finally 7p (nihonium to oganesson). Starting from lawrencium the 5f orbitals are in the core, and probably the 6d orbitals join the core starting from nihonium.
On the other hand, patients who are treated in community mental health centers lack sufficient cancer testing, vaccinations, or regular medical check-ups. Other critics of state deinstitutionalization argue that this was simply a transition to "transinstitutionalization, or the idea that prisons and state-provisioned hospitals are interdependent. In other words, patients become inmates. This draws on the Penrose Hypothesis of 1939, which theorized that there was an inverse relationship between prisons' population size and the number of psychiatric hospital beds. This means that populations that require psychiatric mental care will transition between institutions, which in this case includes state psychiatric hospitals and criminal justice systems. Thus, a decrease in available psychiatric hospital beds occurred at the same time as an increase in inmates. Although some are skeptical that this is due to other external factors, others will attribute this conclusion to a lack of empathy for the mentally ill. There is no argument for the social stigmatization of those with mental illnesses; they have been widely marginalized and discriminated against in society. In this source, researchers analyze how most compensation prisoners (detainees who are unable or unwilling to pay a fine for petty crimes) are unemployed, homeless, and have an extraordinarily high degree of mental illnesses and substance use disorders.
One or more of these steps may, but not necessarily, involve computer-aided drug design. Despite advances in technology and understanding of biological systems, drug discovery is still a lengthy, "expensive, difficult, and inefficient process" with a low rate of new therapeutic discovery. In 2010, the research and development cost of each new molecular entity (NME) was approximately US$1.8 billion. Drug discovery is done by pharmaceutical companies, sometimes with research assistance from universities. The "final product" of drug discovery is a patent on the potential drug. The drug requires very expensive Phase I, II, and III clinical trials, and most of them fail. Small companies have a critical role, often then selling the rights to larger companies that have the resources to run the clinical trials. Drug discovery is different from Drug Development. Drug Discovery is often considered the process of identifying new medicine. At the same time, Drug development is delivering a new drug molecule into clinical practice. In its broad definition, this encompasses all steps from the basic research process of finding a suitable molecular target to supporting the drug's commercial launch.
Sources: en.wikipedia.org
==== Deuteron mass and radius ==== The deuterium nucleus is called a deuteron. It has a mass of 2.013553212544(15) Da (1875.61294500(58) MeV/c2). The charge radius of a deuteron is 2.12778(27)×10−15 m. Like the proton radius, measurements using muonic deuterium produce a smaller result: 2.12562(78) fm.
On January 3, 2020, Cold Stone Creamery announced that it would close its doors on January 31, 2020, in Singapore. In March 2015, Cold Stone opened its first location in Turkey's capital Ankara. In 2015 Cold Stone Creamery opened its first location in El Salvador in Multiplaza Mall and in April 2023, Cold Stone opened its first United Kingdom location in Charing Cross Road. In May 2007, Cold Stone Creamery merged with Kahala Corp to form Kahala-Cold Stone, which collectively owns 8 brands. Doug Ducey, who had served as president and CEO of Cold Stone Creamery since 1995, and future Governor of Arizona, was named CEO of the new company. Kevin Blackwell, the former CEO of Kahala, became chairman of the board and chief strategist. However, in September 2007, Ducey announced he was leaving the company. Blackwell was named CEO. In 2013, the Serruya family, based in Toronto, Ontario, purchased a majority interest in Kahala and changed the name to Kahala Brands to better align with the focus of the business. After a decade of operation, Cold Stone Creamery closed all its outlets in Singapore on January 31, 2020.
=== Video enhancing and analysis systems === Intergraph Government Solutions developed its Video Analyst System (VAS) by building on Video Image Stabilization and Registration (VISAR) technology created by NASA to help FBI agents analyze video footage. Originally used for enhancing video images from nighttime videotapes made with hand-held camcorders, VAS is a tool for video enhancement and analysis offering support of full-resolution digital video, stabilization, frame-by-frame analysis, conversion of analog video to digital storage formats, and increased visibility of filmed subjects without altering underlying footage. Aside from law enforcement and security applications, VAS has also been adapted to serve the military for reconnaissance, weapons deployment, damage assessment, training, and mission debriefing.
Sir John Christopher Willoughby was second in command and took command of the expedition when the two columns united northwest of Johannesburg on 30 December. Although Jameson's men had cut the telegraph wires to Cape Town, they had failed to cut the telegraph wires to Pretoria (cutting a fence by mistake). Accordingly, news of his incursion quickly reached Pretoria and Jameson's armed column was tracked by Transvaal forces from the moment that it crossed the border. The Jameson armed column first encountered resistance very early on 1 January when there was a very brief exchange of fire with a Boer outpost. Around noon the Jameson armed column was around twenty miles further on, at Krugersdorp, where a small force of Boer soldiers had blocked the road to Johannesburg and dug in and prepared defensive positions. Jameson's force spent some hours exchanging fire with the Boers, losing several men and many horses in the skirmish. Towards evening the Jameson armed column withdrew and turned south-east attempting to flank the Boer force. The Boers tracked the move overnight and on 2 January, as the light improved, a substantial Boer force with some artillery was waiting for Jameson at Doornkop. The tired raiders initially exchanged fire with the Boers, losing around thirty men before Jameson realized the position was hopeless and surrendered to Commandant Piet Cronjé. The raiders were taken to Pretoria and jailed.
Sources: en.wikipedia.org
MHD oscillations are damped if the fluid is not perfectly conducting but has finite conductivity, or if viscous effects are present. MHD waves and oscillations are popular tools for the remote diagnostics of laboratory and astrophysical plasmas, for example, the Sun's corona (coronal seismology).
Russia launched a wave of missile attacks across Ukraine, killing at least 47 people. At least 33 people were killed in Kyiv, where the country's largest pediatric hospital was struck. Ten people were killed in Kryvyi Rih, while three were killed in Pokrovsk and one in Dnipro. Attacks were also reported in Kramatorsk and Sloviansk. The Ukrainian Air Force claimed to have shot down 30 of 38 missiles launched during the attacks. Ukraine and Poland signed a security agreement, forming a new volunteer unit called the Ukrainian Legion. The FSB claimed to have foiled a Ukrainian plot which involved a pilot attempting to hijack a Tu-22 bomber.
During the retention period, specimens are considered part of the medical record and must be kept in a CLIA-accredited laboratory to ensure compliant handling and storage conditions. If a specimen is sent out to a non-CLIA biorepository and recalled, the additional testing would not be in compliance. There is an effort to make more biobanks CLIA equivalent as specimen recalls become more common due to expanded testing.
Sources: en.wikipedia.org
Most listings describe it as a short acetylated peptide with the sequence Ac-LKKTETQ, presented as a region of thymosin beta-4. The label is a trade-style name rather than a standardized chemical name, so the exact content of a given vial depends on the supplier.
No. Thymosin beta-4 is a protein of 43 amino acids, while TB-500 is described as a short fragment of it. The two differ in size, structure, and the range of interactions each can support.
Naming for research peptides is not centrally coordinated, so vendors set their own labels and specifications. Differences in stated sequence, molecular weight, or purity documentation usually trace back to those independent labeling choices.
The most common approach is liquid chromatography with tandem mass spectrometry after extraction from blood or urine. Immunoassays exist but are generally treated as screening tools because of cross-reactivity.